CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target
AbstractCK2 genes are overexpressed in many human cancers, and most often overexpression is associated with worse prognosis. Site-specific expression in mice leads to cancer development (e.g., breast, lymphoma) indicating the oncogenic nature of CK2. CK2 is involved in many key aspects of cancer including inhibition of apoptosis, modulation of signaling pathways, DNA damage response, and cell cycle regulation. A number of CK2 inhibitors are now available and have been shown to have activity against various cancers in vitro and in pre-clinical models. Some of these inhibitors are now undergoing exploration in clinical trials as well. In this review, we will examine some of the major cancers in which CK2 inhibition has promise based on in vitro and pre-clinical studies, the proposed cellular and signaling mechanisms of anti-cancer activity by CK2 inhibitors, and the current or recent clinical trials using CK2 inhibitors. View Full-Text
Share & Cite This Article
Chua, M.M.; Ortega, C.E.; Sheikh, A.; Lee, M.; Abdul-Rassoul, H.; Hartshorn, K.L.; Dominguez, I. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals 2017, 10, 18.
Chua MM, Ortega CE, Sheikh A, Lee M, Abdul-Rassoul H, Hartshorn KL, Dominguez I. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals. 2017; 10(1):18.Chicago/Turabian Style
Chua, Melissa M.; Ortega, Charina E.; Sheikh, Ayesha; Lee, Migi; Abdul-Rassoul, Hussein; Hartshorn, Kevan L.; Dominguez, Isabel. 2017. "CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target." Pharmaceuticals 10, no. 1: 18.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.